Enterprise Agents Are Deploying — But 'Widely' Depends on Which Workflows You're Counting

Here's what we changed, and why it matters: we're not forecasting that enterprises are experimenting with agents, or that conversion rates are trending upward, or that infrastructure investment is accelerating. Those are all true. We're forecasting that autonomous agents are *widely deployed in enterprise workflows* — and that target, as previously written, was too vague to score. So we're defining it now, on the record: resolution requires at least three of five major enterprise sectors (finance, healthcare, logistics, retail, manufacturing) to have autonomous agents handling end-to-end workflows in production, confirmed by public earnings disclosures or verified third-party audits. That's the line. Everything below is leading-indicator territory.

With that definition in place, let's be precise about what Q2 data actually shows. The AIApps pilot-to-production conversion figure — 31%, nearly double Q1's 18% — is a leading indicator of deployment intent, not confirmed production depth. We don't have AIApps' denominator: 31% of how many pilots, at what company sizes, in which industries? 'Production' in enterprise software typically means promoted out of staging, not necessarily running autonomously on consequential workflows at scale. The Accenture-Netomi deal is real, but customer service automation is the least regulated, lowest-liability workflow an enterprise can hand to an agent — it's meaningful signal, but it doesn't tell us whether agentic deployment is crossing into underwriting, clinical documentation, or supply chain optimization where the stakes and structural barriers are categorically different. JPMorgan's $19.8B budget reclassification is significant as an organizational intent signal, but infrastructure investment in regulated financial institutions typically precedes deployment by 12–24 months. We're flagging it as a leading indicator, not current-state confirmation.

The counterargument we take seriously — and the one that genuinely constrains our ceiling — is the regulatory and liability structure around autonomous operation in core enterprise workflows. MCP standardization reduces integration friction. It does not resolve audit trail requirements, explainability obligations, or liability assignment when an agent makes a consequential error on a compliance review or a clinical note. Databricks' latest market positioning is telling here: they've shifted from selling model capabilities to selling 'production readiness and governance maturity' — because enterprise buyers in regulated sectors are asking exactly these questions before signing off on autonomous deployment. That's healthy infrastructure-building. It's also evidence that the governance layer hasn't cleared yet.

So why 77%? Our number reflects a genuine acceleration in deployment infrastructure — MCP as de facto standard, conversion rates improving, Alteryx democratizing agent-building to non-technical users — offset by three unresolved constraints: the regulated-industry liability gap, the absence of confirmed autonomous deployment in high-stakes workflows, and the 69% of pilots that still aren't converting. The 1-point move from 76% to 77% isn't conservative timidity — it reflects that Q2 data strengthens the unregulated-workflow side of the ledger while leaving the regulated-workflow question unanswered. We'd move to 82%+ if Q3 earnings calls from financial or healthcare institutions include specific language about autonomous agent operations on core workflows — not AI investment broadly, but agent-specific production deployment. We'd drop below 65% if the Colorado and EU enforcement deadlines trigger a compliance freeze on enterprise agent deployments across high-risk categories, which our current model hasn't fully priced in.